Cassava Sciences | PTIE - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Abbott USD 52.06B 69M 2026-03
Amgen USD 9.19B 532M 2026-03
Biogen USD 18.65B 394.9M 2026-03
Cara Therapeutics USD 20.95M 6.92M 2025-12
Cassava Sciences USD 68.14M 6.26M 2026-03
Eisai JPY 898.99B 9.36B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Geron USD 229.11M 3.24M 2026-03
J&J USD 81.19B 358M 2026-03
Merck USD 45.88B 6.73B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Roche Holding CHF 33.8B 758M 2025-12